Inozyme Pharma Inc Asset Resilience Ratio
Inozyme Pharma Inc asset resilience ratio. Inozyme Pharma Inc (INZY) has an Asset Resilience Ratio of 61.92% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Inozyme Pharma Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Inozyme Pharma Inc (2018–2024)
Asset resilience ratio of Inozyme Pharma Inc from 2018 to 2024. This chart shows how Inozyme Pharma Inc's Asset Resilience Ratio has changed over time. Read Inozyme Pharma Inc (INZY) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Inozyme Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Inozyme Pharma Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $58.93 Million | 61.92% |
| Total Liquid Assets | $58.93 Million | 61.92% |
Asset Resilience Insights
- Very High Liquidity: Inozyme Pharma Inc maintains exceptional liquid asset reserves at 61.92% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Inozyme Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Inozyme Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Inozyme Pharma Inc Asset Resilience Ratio by Year (2018–2024)
Inozyme Pharma Inc asset resilience ratio by year from 2018 to 2024. The table below shows the annual Asset Resilience Ratio data for Inozyme Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 74.69% | $92.01 Million | $123.18 Million | -1.98pp |
| 2023-12-31 | 76.68% | $154.00 Million | $200.85 Million | +8.46pp |
| 2022-12-31 | 68.21% | $94.95 Million | $139.19 Million | -3.41pp |
| 2021-12-31 | 71.62% | $88.48 Million | $123.54 Million | +0.97pp |
| 2020-12-31 | 70.65% | $119.66 Million | $169.36 Million | +38.27pp |
| 2019-12-31 | 32.39% | $15.53 Million | $47.94 Million | +15.86pp |
| 2018-12-31 | 16.53% | $7.20 Million | $43.54 Million | -- |
About Inozyme Pharma Inc
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney… Read more